Prothena appoints director of investor relations and communications

Sep 30, 2020
Jennifer Zibuda joins from Portola Pharmaceuticals

Clinical-stage neuroscience company Prothena has appointed Jennifer Zibuda as its director of investor relations and communications, a new role created due to company growth.

Zibuda joined Prothena on September 28 and reports to Ellen Rose, senior vice president of communications and chief of staff for finance. Zibuda previously spent more than two years with Portola Pharmaceuticals, where she was most recently associate director of investor relations.

She has also held investor relations roles at Alkermes and The Navigators Group, according to her LinkedIn profile.

Prothena is headquartered in Dublin, Ireland, but several members of its executive and communications team are based in the San Francisco Bay Area, which is where Zibuda is based.

‘Starting a new role in this remote work environment actually makes the distance between colleagues in other countries seem less significant to me because everyone is remote,’ Zibuda tells IR Magazine. ‘Prothena is also a small company and was very organized in its onboarding so it makes it a little easier to reach out and get to know everyone.’

Zibuda says she will be focused on new, creative ways to communicate with different stakeholder groups, leveraging virtual communications.

Sign up to get stories direct to your inbox
logo-black logo-black